REVIEW

Leukemia and Lymphoma of Natural Killer Cells

Ritsuro Suzuki

Malignant hematolymphoid disorders arising from NK cells have become widely recognized over the past decade. The two forms of NK-cell malignancy, aggressive NK-cell leukemia (ANKL) and extranodal NK-cell lymphoma of nasal type (ENKL) are both characterized by the proliferation of tumor cells with an NK-cell like immunophenotype. ANKL usually presents with bone marrow tumor cells accompanied by circulating leukemic cells, and hepatosplenomegaly is a common clinical feature. ENKL most frequently affects the nasal or paranasal regions, with cutaneous involvement also being common. Approximately 70 percent of ENKL present with localized tumor cells, and follow an indolent clinical course, but, in advanced cases, tumors rapidly expand and are frequently fatal. Tumor cells from both ANKL and ENKL are surface CD3⁻ and CD56⁺ but differ in their expression of CD16. Epstein-Barr virus (EBV) is found in most cases of NK-cell leukemia/lymphoma, suggesting an oncogenic role, but patients may have biclonal or polyclonal populations of malignant cells based on differential EBV genome incorporation. NK-cell neoplasms are frequently resistant to chemotherapy due to p-glycoprotein expression and associated multidrug resistance. The prognoses of both localized and advanced stages of NK-cell malignancies are worse than most other lymphoid malignancies, but studies are currently underway to assess the safety and efficacy of novel chemoradiotherapy regimens for the treatment of these neoplasms.

INTRODUCTION

The classification of lymphoid neoplasms has changed much in recent years. In the Working Formulation¹, lymphocyte lineage was not a factor in neoplasm classification, but the Revised-European-American Classification for Lymphoid Neoplasms (REAL Classification) once again adopted these standards, originally in place in the Kiel Classification^{2,3}. However, neoplasms arising from NK-cells were not correctly defined in the REAL Classification, and inclusion of NK-cell neoplasms did not occur until the new World Health Organization (WHO) Classification⁴. In addition to aggressive NK-cell leukemia (ANKL) and extranodal NK-cell lymphoma, nasal type (ENKL), which are listed in the WHO Classification, there are several provisional categories of NK-cell neoplasms (Table 1). In this review, I describe the history of NK-cell neoplasms and the future prospects for disease management and treatment for these malignancies with extremely poor prognoses.

Definition of NK-cells

NK-cells were first recognized as a functional subset of lymphocytes mediating major histocompatibility complex-nonrestricted cytotoxicity⁵. NK-cells are morphologi-

cally large granular lymphocytes (LGLs), with germline T-cell receptor (TCR) and immunoglobulin gene configurations. Additionally, they are surface CD3 (sCD3)-negative and CD56-positive⁶. Based on these results, NK-cells are considered as the third lineage of lymphocyte distinct from T- and B-cells. Currently, two types of NK-cells are now proposed, cytotoxic NK-cells and immunoregulatory NK-cells⁷. It remains unclear whether these are distinct NK-cell subtypes or if differential cytokine exposure causes phenotypic interchangeability. During development, NK-cells arise from T/NK bi-potential common progenitors^{8,9}. Therefore, NK-cells are functionally and phenotypically very similar to T-cells, particularly cytotoxic T-cells; this renders the differential diagnosis of NK-cell neoplasms difficult.

Table 1. List of NK-cell neoplasms

Disease	Abbreviation
1. Precursor NK-cell neoplasms	
(1) Myeloid/NK cell precursor acute leukemia	MNKL
(2) Blastic NK cell lymphoma	BNKL
2. Mature NK-cell neoplasms	
(1) Aggressive NK-cell leukemia	ANKL
(2) Extranodal NK-cell lymphoma, nasal type	ENKL
(3) Chronic NK-cell lymphocytosis*	CNKL

* Uncertain malignant potential.

Received : Aug 22, 2005

Accepted : Aug 23, 2005

Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan.

Address correspondence and reprint request to Ritsuro Suzuki, Division of Molecular, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan

Recognition of NK-cell leukemia and lymphoma

Leukemia of NK-cells was first described by Fernandez *et al.* and Koizumi *et al.* in 1986 as “aggressive NK-cell leukemia (ANKL)” (Fig. 1)^{10,11}. Both groups demonstrated NK-activity and IL-2 responsiveness in the leukemic cells and concluded the neoplasms were of NK-cell origin. Imamura *et al.* also identified leukemia of NK-cell origin, but their findings were not published for several years¹². Based on cellular morphology, these malignancies were considered a type of LGL leukemia¹³, but we now know that this classification encompasses a very heterogeneous collection of diseases. Alternative names for ANKL were aggressive LGL leukemia, non-T LGL leukemia, and NK-LGL leukemia, and in the REAL Classification this disease entity was given the new category LGL leukemia, NK-cell type (Fig. 1)³. However, this categorization emphasized the morphological features of the leukemic cells, rather than cell origin. Chronic T-LGL leukemia, also classified as an LGL leukemia, exhibits the same cellular morphology as ANKL, but dramatically differs in cell origin, phenotype, genotype, function and clinical course, and these differences are summarized in Table 2^{13,14}. These differences led to the recognition of ANKL as a separate entity from T-LGL leukemia in the WHO Classification⁴.

Lymphoma of NK-cells was originally incorrectly identified as T-cell lymphoma of nasal origin because of the phenotypic similarity of T-cells and NK-cells¹⁵. Lethal midline granuloma was a disease of undetermined neoplastic signifi-

cance occurring in the mid facial area, and biopsied specimens from these lesions exhibited marked necrosis with inflammatory changes. Ishii *et al.* first recognized the presence of tumor cells expressing CD3 in this lesion and termed this disease “nasal T-cell lymphoma”¹⁵. Further characterization of this tumor revealed angiocentric infiltration of tumor cells, and the terminology of “angiocentric T-cell lymphoma” was proposed¹⁶⁻¹⁸. In the REAL Classification, this type of nasal lymphoma was considered an angiocentric lymphoma, together with pulmonary lymphomatoid granulomatosis of B-cell origin, based on morphological features³. However, Suzumiya *et al.* demonstrated that tumor cells of this nasal lymphoma express cytoplasmic CD3 and CD56, but not T-cell receptors, suggesting their NK-cell origin¹⁹. On November 11-14, 1994, a workshop on NK-cell lymphomas was held in Hong Kong²⁰. At this meeting, tumor angiocentricity was not considered an absolute characteristic of nasal NK-cell lymphomas, and similarities with non-nasal NK-cell lymphomas were confirmed. Thus, the nomenclature of “nasal and nasal-type T/NK-cell lymphoma” was employed. In the WHO Classification, the extranodal origin of this lymphoma was emphasized, and the terminology “extranodal NK/T-cell lymphoma (ENKL), nasal-type” was adopted⁴.

Clinical characteristics of aggressive NK-cell leukemia

ANKL is characterized by the systemic proliferation of NK-cells, with a highly aggressive clinical course. It

	NK-cell leukemia	NK-cell lymphoma
Original terminology	Aggressive NK-cell leukemia (1986)	Nasal T-cell lymphoma (1982)
Alternative nomenclature	Aggressive LGL leukemia Non-T LGL leukemia NK-LGL leukemia	Angiocentric T-cell lymphoma Nasal NK-cell lymphoma
REAL Classification (1994)	LGL leukemia, NK-cell type	Angiocentric lymphoma
Hong Kong Workshop Report (1996)		Nasal and nasal-type T/NK-cell lymphoma
WHO Classification (2001)	Aggressive NK-cell leukemia	Extranodal NK/T-cell lymphoma, nasal-type
Lugano Meeting (2005)	Generic NK-cell lymphoma (?)	

Fig. 1. History of NK-cell leukemia/lymphoma nomenclature. The classification and nomenclature of NK-cell leukemia and lymphoma have changed over time, and different classification schemes have been proposed. Aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type are separate entities in the new WHO Classification, and the “generic NK-cell lymphoma” category was recently proposed to integrate these two diseases by Weisenburger in the 9th International Conference on Malignant Lymphoma 2005.

Table 2. Phenotypic profile of NK-cell neoplasms and other related/CD56⁺ T-cell lymphomas

	Aggressive NK-cell leukemia	Extranodal NK-cell lymphoma	Hepatosplenic T-cell lymphoma	Enteropathy-type T-cell lymphoma	T-LGL leukemia
CD2	+	+	+	+	+
sCD3	–	–	+	+	+
cyCD3	+	+	+	+	+
CD4	–	–	–	–	–
CD5	–	–	+/-	–	+
CD7	+/-	+/-	+/-	+	+
CD8	+/-	+/-	+/-	+	+/-
CD16	+(/-)	–	+/-	–	–
CD43	+	+	+	+	+
CD45RO	+	+	+	+	+
CD56	+	+	+(/-)	+/-	–
CD57	–	–	-(/+)	–	+
TCR	–	–	+	+/-	+
Granzyme B	+	+	+/-	+	–
TIA-1	+	+	+	+	–
EBV	+	+	–	–	–

accounts for less than 1% of lymphoid malignancies in Japan²¹, and is also rare in Hong Kong, Korea and Taiwan (personal communications). The NK-cell Tumor Study Group in Japan reported the largest series in the literature, examining 22 patients²². When data from several reports are considered together, ANKL predominantly occurs in younger patients with a median age around 40 years without any sex predilection^{12,14,22-32}. Patients frequently present with B-symptoms, such as fever, night sweat or weight loss, and hematological findings are consistent with leukemia, including circulating and bone marrow leukemic cells, neutropenia, anemia and thrombocytopenia. Hepatosplenomegaly frequently occurs, but does not affect all patients. Cutaneous or central nervous system involvement is uncommon. Interestingly, hypersensitivity to mosquito bites is sometimes a preceding feature of NK-cell leukemia, particularly in younger patients³³⁻³⁵. Additionally, leukemic progression of nasal NK-cell lymphoma was also reported³⁶. Leukemic cells exhibit a LGL morphology, surfaceCD3[–] CD2⁺ CD56⁺ immunophenotype, and germline configurations of T-cell receptor genes^{22,23,29}. CD16 and cytoplasmic CD3 are positive in many cases. Expression of CD122 and the lack of CD25 suggest ANKL cells originate as cytotoxic NK-cells²², rather than immunoregulatory NK-cells⁷. As with ENKL of nasal type, tumor cells are Epstein-Barr virus (EBV) positive^{22-24,27,29-31}. Although no recurrent cytogenetic abnormalities have been identified, alterations in chromosome 7

occur relatively frequently in ANKL²². Chemotherapy for acute leukemia or aggressive lymphoma is not highly effective, resulting in poor prognosis for this disorder. Resistance to chemotherapy is likely mediated by p-glycoprotein, a product of *MDR1* gene³⁷, that is expressed in this type of lymphoma³⁸⁻⁴⁰. Most affected patients die within 2 years, many within 6 months after diagnosis^{22,23}.

Clinical characteristics of extranodal NK-cell lymphoma, nasal type

ENKL is characterized by extranodal involvement, particularly the nasal/paranasal area, and is referred to as “nasal NK-cell lymphoma” in this situation. ENKL is rare in Western countries, but is more frequent in East Asia and Central and South America⁴¹⁻⁴⁶. It represents 3.3% of all non-Hodgkin's lymphoma in Japan²¹, 6% in Hong Kong⁴⁷, 8% in Korea⁴⁸, and 5% in Taiwan⁴⁹. ENKL predominantly occurs in middle-aged patients, and it is significantly more prevalent in men. This type of lymphoma, particularly advanced-stage cases, is associated with hemophagocytic syndrome, and some patients develop the sudden onset of pancytopenia or multi organ failure⁴¹⁻⁴⁵. Histopathologically, the lymphoma cells are polymorphous and show an angiocentric growth pattern, with subsequent vascular obstruction and prominent necrosis. The immunophenotype of tumor cells resembles that of NK-cells (surfaceCD3[–] cytoplasmicCD3e⁺ CD56⁺) in

most cases^{19,50-52}, but, in rare circumstances, is more consistent with a T-cell phenotype. Most ENKL cells also express cytotoxic granule-associated proteins, such as perforin, granzyme B, TIA-1, and granzyme M⁵³⁻⁵⁹. Increased expression of Fas-ligand is commonly seen in ENKL, but this is non-specific and seen in a number of aggressive lymphomas^{55,60-62}. NK inhibitory receptors, such as CD94 or NKG2A are also expressed in NK-cell neoplasms, but such expression is not uniform or consistent⁶³⁻⁶⁷. However, expression of CD94 is reported to confer a better prognosis in ENKL⁶⁷. EBV is found in the tumor cells in virtually all cases, and ENKL, nasal-type is now regarded as an EBV-related neoplasm⁶⁸⁻⁷⁰. Deletions of the long arm of chromosome 6 are frequently seen in ENKL^{71,72}, but this abnormality is also commonly seen in other types of lymphoma^{73,74}. Approximately 70% of ENKL patients present with limited stage I or II disease^{52,75-82}. In addition to the paranasal area, tumors frequently occur in the skin and soft tissue^{29,83-90}. Regional lymph nodes may be involved, but restriction to nodal disease is extremely rare⁹¹. The clinical course of NK-cell lymphoma varies with the clinical stage. Patients with limited stage disease (usually nasal disease) typically have an indolent course with tumor restriction to the original site, but others suffer rapid progression to systemic dissemination often accompanied by hemophagocytosis or disseminated intravascular coagulation. Radiotherapy is effective in the treatment of ENKL, but, as with ANKL, chemotherapy is of limited effectiveness due to the expression of p-glycoprotein³⁷⁻⁴⁰, which mediates the ac-

tive transport of anthracyclines and vinca alkaloids. Therefore, radiotherapy is typically undertaken in patients with limited stage diseases⁹²⁻¹⁰¹, with or without subsequent chemotherapy. No effective therapies exist for advanced cases, however.

Putative precursor NK-cell neoplasms

At the Hong Kong Workshop for Extranodal T/NK-cell lymphoma in 1994, Drs. Suchi and Mori presented two previously unrecognized forms of CD56-positive lymphoma²⁰. These cases were characterized by unusual skin involvement, blastic morphology, sCD3⁻ CD56⁺ TdT⁺ phenotype without B-cell markers, and the lack of Epstein-Barr virus (EBV), and the nomenclature of "blastic NK-cell lymphoma" was assigned to this disease²⁰. There are several reports of this type of lymphoma, which were not specifically diagnosed due to their unusual phenotype that is not consistent with a clear cellular origin^{87-89,102-108}. These tumors were hypothesized to originate from precursor NK-cells due to their phenotypic similarity (Fig. 2), but many blastic NK-cell lymphoma (BNKL) express CD4^{87-89,104-108}. Recently, many clinicopathologic differences between CD4-positive and -negative BNKL have been described, suggesting that these two subgroups constitute distinct diseases^{109,110}. However, it remains unclear whether CD4 expression or anatomic location (i. e., cutaneous vs. non-cutaneous) should be the primary factor determining categorization. Occasionally, leukemic cases of

Fig. 2. Differentiation pathway of NK-cells and corresponding NK-cell neoplasms.

NK-cells differentiate from stem cells through the myeloid antigen positive NK/ T bi-potential progenitor and the lineage committed progenitor. The myeloid/NK cell precursor acute leukemia originates from the myeloid antigen positive progenitor, and blastic NK-cell lymphoma are derived from a relatively mature, NK-cell lineage committed progenitor. Mature NK-cell neoplasms, aggressive NK-cell leukemia, extranodal NK-cell lymphoma of nasal and extranasal origin, and chronic NK-cell lymphocytosis arise from transformed mature NK-cells.

this tumor have been reported¹¹¹⁻¹¹⁶, but no prominent clinicopathologic differences between the leukemic and lymphomatous types have been identified¹¹⁰. Several groups have proposed that CD4⁺ BNKL arise from the precursors of plasmacytoid dendritic cells (pDCs)^{117,118} or plasmacytoid monocytes¹¹⁹, on the basis of CD123 expression and interferon production by the tumor cells. However, pDCs are normally present in lymph node and are rare in the skin. Additionally, CD56 is not expressed on normal pDCs^{120,121} except for a very minor population^{122,123}, and CD123, which is expressed on a variety of normal and malignant hematopoietic cells is not a specific marker for pDCs^{124,125}. CD4⁺/CD56⁻CD123⁺ leukemia/lymphoma with pDC features is the real pDC malignancy^{126,127}. Thus, the true origin of BNKL needs further studies.

In 1997, another type of immature CD56-positive hematologic tumor was identified as “myeloid/NK cell precursor acute leukemia” (Fig. 2)¹²⁸. This leukemia was characterized by pronounced extramedullary involvement, immature lymphoblastoid cellular morphology without myeloperoxidase reactivity, a CD7⁺, CD33⁺, and CD56⁺ phenotype, myeloid chemosensitivity and poor prognosis. These cases were classified as AML M0 according to the FAB classification^{129,130}, and were distinct from CD56-positive tumors of myeloid/NK cell acute leukemia with mature promyelocytoid morphology¹³¹, as well as BNKL⁹⁹. However, this form of leukemia was later found to exhibit different clinical characteristics from CD7⁻ or CD56⁻ AML M0¹³², and was thus a distinct disease entity among AML subclasses.

These CD56-positive immature leukemia/lymphomas are included in the NK-cell Tumor Study Group classification scheme, but have not yet been shown to originate from precursor NK-cells. Strictly, these diseases should be regarded as CD56-positive immature hematolymphoid tumors, but the phenotypic similarities to NK-cell precursors may facilitate

our understanding of these tumors. The NK-cell Tumor Study Group has proposed a provisional classification scheme of NK-lineage malignancies including these ill-defined diseases^{44,133}.

Other CD56-positive malignancies to be differentially diagnosed

CD56 is not a specific NK-cell marker, and several CD56-positive tumors have been identified (Table 3). In acute myeloid leukemia (AML), CD56 is expressed in approximately 20% of cases, particularly those of the monocytic lineage¹³⁴⁻¹³⁶. Although AML is a heterogeneous disease, the expression of CD56 suggests a poor prognosis in AML in general¹³⁷⁻¹³⁹, or for several specific subtypes¹⁴⁰⁻¹⁴⁴. CD56 was first reported as a prognostic factor for patients with AML M2 with the t(8;21)(q22;q22) translocation¹⁴⁰, but this has not been verified by other groups. In the meantime, several groups have shown the prognostic significance of CD56 expression in acute promyelocytic leukemia with the t(15;17)(q22;q21) translocation¹⁴¹⁻¹⁴⁴. Differentiation of non-nasal NK-cell lymphomas occurring in the skin or soft tissue from extramedullary AML is particularly important for prognostic and therapeutic decisions. However, in acute lymphoblastic leukemia CD56 expression is relatively rare^{134,145-147}.

CD56 is also expressed in a subset of T-cells, as well as 5-20% of peripheral T-cell lymphomas¹⁴⁸⁻¹⁵³. Some conditions have been described as “NK-like T-cell lymphoma”^{86,90,154,155}, but this label does not accurately reflect the T-lymphocyte origin of this lymphoma and was therefore not included in the current WHO classification¹⁵⁶. Because NK-cell and T-cell lymphomas share the cyCD3⁺ CD56⁺ phenotype, and the expression of sCD3 and cyCD3 is usually indistinguishable on paraffin sections, appropriate diagnosis is

Table 3. CD56-positive tumors other than NK-cell lineage

Category	Frequency	Subtype	Significance of CD56 expression
Acute myeloid leukemia	20%	Monocytic leukemia (FAB M4/M5)	
		M2 with t(8;21)	Possible prognostic factor
		Acute promyelocytic leukemia	Prognostic factor
Peripheral T-cell lymphoma	5-10%	Anaplastic large cell lymphoma	Possible prognostic factor
		Peripheral T-cell lymphoma, unspecified	Not prognostic
Multiple myeloma	50-70%		Not prognostic
Small round cell tumor	Most cases	Neuroblastoma	
		PNET	
		Ewing sarcoma	
		Wilms tumor	
		Rhabdomyo sarcoma	
		Small cell lung cancer	

essential^{50,51,157}. Cells derived from hepatosplenic T-cell lymphoma and enteropathy-type T-cell lymphoma are usually CD56 positive (Table 2)^{150,158-161} but other T-cell lymphomas do not display consistent CD56 expression. On the other hand, CD56 expression is a strong prognostic factor for anaplastic large cell lymphoma¹⁵², but not peripheral T-cell lymphoma, unspecified¹⁵³.

As CD56 is a neural cell adhesion molecule, it is also expressed in non-hematologic tumors, including neuroectodermal tumors. Its expression has been documented in neuroblastoma^{162,163}, PNET¹⁶², Ewing sarcoma¹⁶², Wilms tumor¹⁶⁴, rhabdomyosarcoma¹⁶², malignant schwannoma¹⁶³ and small cell lung cancer^{165,166}. As these tumors can also exhibit a small round morphology, proper exclusion of these tumors from the differential diagnosis is essential.

Genetic features and oncogenes

Currently, no genetic abnormalities specific for NK-lineage neoplasms have been identified. Deletion of the long arm of chromosome 6 was reported to be the most frequent cytogenetic aberration^{71,72}, but no target or tumor suppressor genes have been identified in this region to date¹⁶⁷⁻¹⁶⁹. Additionally, no consistent oncogenes or tumor suppressors have been identified for NK-cell lymphoma (Table 4). Homozygous deletion of p15 and p16/p14 were identified in approximately 30% of the cases studied^{170,171}, and mutation of the *FAS* gene^{172,173} and methylation of p73¹⁷⁴, *SHIP1*¹⁷⁵, *hMLH1*¹⁷⁶, p16¹⁷⁶, and *RARβ*¹⁷⁶ have been identified in more than half of the cases. Mutation of *β*-catenin¹⁷⁷⁻¹⁷⁹ and methylation of p21 and p15 were observed less frequently^{177,180}, but mutation of *N/K/H-RAS* and *N/c-MYC* genes were found in only a small minority of cases^{171,177-179}. Ethnicity also affects genetic alterations in NK-cell lymphoma including differences between Japanese and Chinese pa-

tients for p73^{174,180}, p53^{178,179,181}, and c-Kit¹⁸² alterations. A more precise characterization of the genetic changes associated with NK-cell lymphoma, as well as any role for EBV infection, needs further clarification.

Complementary genetic hybridization (CGH) has been used to investigate genetic aberrations in NK-cell lymphoma^{175,183-186}. These studies identified the gain of 1p, 6p, 11q, 12q, 17q, 19p, 20q and Xp, and the loss of 6q, 11q, 13q and 17p in several different samples, but several differences were also identified between the cases examined. Recently, an array-based CGH study was performed and identified new gain/loss regions, which could not be identified using conventional CGH analyses¹⁸⁷. This study also demonstrated clear genetic difference between ANKL and ENKL, suggesting that these are two distinct disease entities. This data supports the clinicopathologic features identified between ANKL and ENKL¹⁸⁸. These differences may represent differences in ENKL between localized and advanced cases, but further studies are needed to clarify this issue.

Epstein-Barr virus (EBV)

In most mature NK-cell leukemias and lymphomas, clonal EBV proliferation has been found in tumor cells^{23,24,41-44,68,189,190}. Most tumors are associated with EBV with latency II with the occasional absence of LMP-1^{30,191,192}. Binding of EBV to target cells is mediated by CD21 in B-cells¹⁹³ and NK/T-cells¹⁹⁴, but recent studies suggest the existence of other binding pathways, particularly in epithelial cells¹⁹⁵. Although the EBV-receptor remains unclear in CD21-negative NK-cell tumors, human leukocyte antigen class II *β* plays an important role for the internalization of EBV in NK-cells¹⁹⁶. The EBV genome is linear in the viral particles, but circularizes in an episomal form after infection with a uniquely sized terminal repeat¹⁹⁷. Therefore, EBV can

Table 4. Aberrations of oncogenes in NK-cell leukemia/lymphoma

Gene	Type of aberration	Frequency	Reference
<i>p73</i>	Methylation	94% (China, Hong Kong), 10% (Japan)	174, 180
<i>hMLH1</i>	Methylation	60-70% (China, Hong Kong)	176
<i>RARβ</i>	Methylation	56%	176
<i>SHIP1</i>	Methylation	91%	175
<i>p16</i>	Methylation	63%	176
<i>p15</i>	Methylation	48%	176
<i>p15/p16</i>	Homozygous deletion	38%	170, 171
<i>Fas</i>	Mutation	50-60%	172, 173
<i>p53</i>	Mutation	20-60%	178, 179, 181
<i>c-KIT</i>	Mutation	5-71% (China), 16-22% (Japan)	178, 182
<i>β-catenin</i>	Mutation	16-30%	177-179
<i>N/K/H-Ras</i>	Mutation	Rare (< 5%)	171, 177-179
<i>N/c-Myc</i>	Amplification/ Mutation	None	171

be detected by Southern blotting as a single band, but genomic integration of EBV occurs in approximately 10% of the cases¹⁹⁸. Meanwhile, biclonal or polyclonal EBV genomes are found in occasional cases, and the lytic phase of EBV infection has been seen in some overlapping cases. HANK-1 is a cell line established from tumor cells of disseminated NK-cell lymphoma¹⁹⁹. Southern blot analysis using a probe specific for the EBV terminal repeat demonstrated that this cell line was derived from a minor clone in original tumor cells (Fig. 3). In most cases, isolated tumor cells have the same phenotype of typical NK-cell neoplasms, suggesting a common tumor origin with differential EBV clonality. Because the EBV genome exists within cells as an episome without integration in most cases, cellular reinfection is possible causing the appearance of different EBV clones. This has been demonstrated in other cases^{167,200,201}, and therefore, EBV monoclonality is not always required for the diagnosis of NK-cell malignancies.

The presence of EBV-DNA in the serum/plasma of patients was first recognized in nasopharyngeal carcinoma using polymerase chain reaction (PCR)²⁰². Later, it was also found in other EBV-associated tumors including NK-cell lymphoma²⁰³. Spontaneous death of tumor cells leads to the release of EBV DNA, and the presence of EBV DNA in the serum does not necessarily indicate the presence of active EBV in the circulating blood. Therefore, the upper size limit of detectable EBV-DNA is 500 bp, and the size less than 300

bp is desirable for diagnosis or detection of minimal residual disease²⁰⁴. Infection-competent EBV is found in the lymphocytes of patients with acute or chronic EBV infection²⁰⁵, and PCR using peripheral mononuclear cells or whole blood is applied for these patients²⁰⁶. Although this is a more sensitive method than serum/plasma PCR^{207,208}, it is not suitable because it can also detect bystander EBV in immunocompromised patients. A prospective study comparing the prognostic significance between plasma and whole blood as templates for real-time PCR is now under way.

Cell lines

After the initial recognition of NK-cell leukemia/lymphoma, many cell lines were established from primary tumors that have been invaluable research tools^{209,210}. The cell lines derived from NK-cell neoplasms and related disorders are listed in Table 5^{10,199,200,211-220}. The first NK-cell tumor line was established by Yodoi *et al.* in 1983 from a boy with mediastinal lymphoblastic lymphoma²¹¹. Although much relevant clinical information from this case was not provided, the diagnosis according to the current classification scheme seems to fall within the category of ENKL. Likewise, various diagnostic terms were used in the original description of different cell lines, but all can be sorted into three categories, ANKL cell lines^{10,212-214,217,220}, ENKL cell lines^{199,200,211,215,218,219}, and other NK-cell lines^{216,219}. Several NK-cell lines with abnormal karyotypes have been established from patients without defined malignancies, such as hypersensitivity to mosquito bite, chronic active EBV infection (CAEBV) and hydroa vacciniforme-like eruption. The ability to establish cell lines from these patients supports the hypothesis these diseases are premalignant conditions that may progress to NK-cell leukemia/lymphoma. Most of these cell lines were established from Japanese patients, and are phenotypically similar to the original neoplasms, being positive for CD56 and EBV, and IL-2 dependent. Cell lines derived from ENKL and other categories were all established from Japanese patients and are uniformly positive for CD56 and EBV. In contrast, several lines were established from non-Oriental subjects, and these are occasionally negative for CD56^{213,214} or EBV^{217,220}. Existence of CD56 may not be essential for the leukemogenesis of NK-cell leukemia. The absence of EBV is consistent with a diagnosis of ANKL and further differentiates it from ENKL^{22,25,28,32}. These cell lines are faithful replicas of the actual *in vivo* NK-cell leukemias/lymphomas. Further studies, particularly genetic investigations, on these cell lines will provide invaluable information on the diagnosis and treatment of NK-cell neoplasms.

Relationship to chronic active EBV infection

CAEBV is a peculiar situation mainly occurs in children

Fig. 3. Southern blotting of EBV terminal repeat in the HANK-1 cell line.

Southern blot analysis was performed using a probe targeting the EBV terminal repeat. The nasal-type NK-cell lymphoma cell line HANK-1 was derived from a minor lymphoma clone, which differed from the major clone in the size of the EBV terminal repeat. Monoclonality with respect to EBV is not always required for the diagnosis of extranodal NK-cell lymphoma.

Table 5. Cell lines derived from NK-cell neoplasms and related disorders.

Cell line	Age, sex	Ethnicity	Original description of disease	CD56	EBV	Cytokine dependency	Ref.
Aggressive NK-cell leukemia cell line							
(Unnamed)	71 M	White	Aggressive NK-cell leukemia	ND	ND	IL-2	10
NK-92	50 M	Unknown	LGL-NHL with BM involvement	+	+	IL-2	212
TKS-1	21 M	Japanese	Aggressive LGL leukemia	— *	ND	IL-2	213
NKL	62 M	White	NK-LGL leukemia	— *	—	IL-2	214
KYHG-1	45 F	Japanese	Aggressive NK-cell leukemia	+	—	IL-2	217
IMC-1	42 M	Native American	Aggressive NK-cell leukemia	+	—	IL-2	220
Extranodal NK-cell lymphoma cell line							
YT	15 M	Japanese	Acute lymphoblastic lymphoma with thymoma	+	+	No	211
HANK-1	46 F	Japanese	Nasal-type NK-cell lymphoma	+	+	IL-2	199
NK-YS	19 F	Japanese	Nasal NK-cell lymphoma	+	+	IL-2	215
SNK-1	24 F	Japanese	Nasal NK-cell lymphoma with CAEBV	+	+	IL-2	200
SNK-3	44 M	Japanese	Nasal NK-cell lymphoma	+	+	IL-2	219
SNK-6	62 M	Japanese	Nasal NK-cell lymphoma	+	+	IL-2	218
Other NK-cell line							
KAI3	13 M	Japanese	Hypersensitivity to mosquito bite	+	+	IL-2	216
SNK-5	14 F	Japanese	CAEBV	+	+	IL-2	219
SNK-10	17 M	Japanese	CAEBV	+	+	IL-2	219
SNK-11	16 F	Japanese	Hydroa vacciniforme-like eruption	+	+	IL-2	219

* CD56 was positive in the patients' original leukemic cells.

or young adults with waxing and waning symptoms^{205,221-223}. Most patients present with fever, fatigue, lymphadenopathy and/or hepatosplenomegaly, and the EBV genome can be found in peripheral lymphocytes. These symptoms resolve with or without treatments such as anti-inflammatory drugs or steroids but recur after months or years. Occasionally, *bona fide* NK- or T-cell malignancies develop, and pursue fatal clinical course^{201,224}. Etoposide-containing chemotherapy is effective²²⁵ and a cure can be obtained with hematopoietic stem cell transplant^{192,226}, but the timing of treatment is difficult because of the fluctuating clinical course. CAEBV is not simply an EBV infection, but it represents an indolent lymphoproliferative disorder. Young patients with CAEBV need careful observations to judge the timing of treatment. In the future, optimal therapeutic strategies for CAEBV need to be further explored.

CAEBV typically develops in younger patients after an initial EBV infection, but cases in older individuals are sometimes reported^{219,223,224,227}. The diagnosis of such cases relies on the presence of the EBV genome in peripheral blood as detected by PCR. However, the EBV genome is also present

in the plasma of patients with EBV-positive malignancies including NK-cell neoplasms, and often indicates of the presence of occult malignancies, particularly in older patients. A comprehensive examination for malignancies is essential in elderly patients before a confident diagnosis of CAEBV can be made.

Chronic NK-lymphocytosis

Chronic NK-lymphocytosis (CNKL) is characterized by a chronic increase in the number of peripheral blood NK-cells without lymphadenopathy or organomegaly^{14, 42, 228, 229}. Clinically, the disease presents with an indolent course, and no cytogenetic abnormalities are usually found. Although the disease itself has uncertain malignant potential, rare cases may develop into ANKL²³⁰⁻²³². However, this may represent the presence of occult ANKL mis-categorized as CNKL rather than transformation. Therefore, careful observation is needed for CNKL patients. Because EBV is not usually found in CNKL, testing for EBV may facilitate the differential diagnosis²³³. Seroreactivity to

HTLV-II has been reported in CNKL²³⁴, but no evidence of viral DNA was found in the increased NK-cells²³⁵. CNKL is also associated with reactive conditions against viral infections or underlying solid tumors^{14,228}. Careful whole-body examination is therefore recommended during the clinical management of patients with CNKL.

Therapy for localized extranodal NK-cell lymphoma

Radiotherapy alone has been used for the treatment of limited stage of ENKL^{92,95,97}, but the 5-year overall survival (OAS) is approximately 50%. In other subtypes of non-Hodgkin's lymphoma of similar clinical stage, 3 to 4 courses of chemotherapy followed by radiotherapy is now a standard therapy with 5-year overall survival rates of more than 80%^{236,237}. However, this strategy is not effective for the treatment of NK-cell lymphoma. The 5-year overall survival rate is around 40%, which is comparable to or lower than the survival rate seen with radiotherapy alone^{73,75,84,94,95,97}.

Recently, several groups have treated patients with irradiation of more than 45 to 50 Gy followed by short courses of chemotherapy, and the reported 5-year OAS of this procedure reaches 70%^{93,95-97}. However, the initial radiotherapy may miss underlying minimal lesions outside the radiation field. Therefore, a strategy of simultaneous chemoradiotherapy, as used for solid tumors, such as esophageal, laryngeal and lung cancers, may be beneficial for the treatment of ENKL²³⁸⁻²⁴⁰. Currently, the Japanese Clinical Oncology Study Group is performing a prospective evaluation for localized nasal NK/T-cell lymphoma.

Therapy for ANKL or advanced ENKL

Most patients with advanced disease tend to be treated with chemotherapy, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or third generation anthracycline-containing regimens, but most patients respond poorly and die within several months. Several reports demonstrated successful treatment using hematopoietic stem cell transplantation (HSCT) for these diseases²⁴¹⁻²⁵². Currently, HSCT is the only therapy expected to be curative in advanced cases. However, the results of transplant during relapse are poor, and this requires the development of more effective chemotherapeutic regimens for NK-cell neoplasms.

Aviles *et al.* described an active combination chemotherapy for advanced nasal NK/T-cell lymphoma, CMED (cyclophosphamide 2 g/m² and methotrexate 200 mg/m² on day 1, etoposide 300 mg/m² on day 1 and 2, and dexamethasone 20 mg/m² on day 1 to 4, supplemented by granulocyte colony stimulating factor on day 2 to 13)²⁵³. They treated 32 patients of stage III/IV disease with three courses of CMED therapy with an interval of two weeks, accompanied by 50 Gy irradiation of the nasal area and another three courses of CMED

therapy. The complete remission rate and actuarial 5-year overall and disease free survival rates were 65%, but no other reports using this treatment regimen have been published. Yong *et al.* achieved good results with another novel chemoradiotherapy using L-asparaginase 6,000 IU/m² and dexamethasone 10 mg/body on days 1 to 7, and vincristine 1.4 mg/m² on day 1²⁵⁴. Although the treatment schedule was not uniform, 18 CHOP refractory patients were treated with this regimen from one to six courses with intervals of 21 to 28 days, followed by radiotherapy of 50 to 70 Gy (median: 56 Gy). In addition, several case reports claim an excellent efficacy of L-asparaginase in the treatment of refractory NK-cell malignancies^{246,255,256}.

Recently, the NK-cell Tumor Study Group started a phase I trial of a new combination chemotherapy named SMILE. The SMILE regimen consists of a steroid hormone, methotrexate, ifosfamide, L-asparaginase and etoposide, and is a dose-finding study for methotrexate and etoposide (Fig. 4). Methotrexate is administered on the first day, and etoposide and ifosfamide are given from the day after. This schedule is based on *in vitro* pharmacokinetic studies by Kano *et al.*^{257,258}, including unpublished observations. They showed an additive effect of etoposide and ifosfamide when administered on simultaneous days and a synergistic effect of methotrexate when given before these two agents. When methotrexate and other drugs are used simultaneously, they are antagonistic. The toxicity and efficacy of SMILE therapy are now being prospectively evaluated.

Conclusion

Mature NK-cell tumors arise as two distinct entities, ANKL and ENKL. Clear differences exist between these conditions, but ANKL and stage IV ENKL can clinically be managed with the same therapeutic strategy. The mechanism of tumorigenesis remains unclear for both ANKL and ENKL,

Fig. 4. Summary of SMILE chemotherapy. Methotrexate is given on the initial day of SMILE chemotherapy, accompanied by a 3-day course of etoposide, ifosfamide and dexamethasone (days 2-4). Because of the absence of myelosuppressive adverse reaction and a half-life of 1.3 days, L-asparaginase will be given on every other days from day 8 to day 20 (7 doses). The SMILE therapy will be repeated with an interval of 28 days. Doses of each agent will be determined in a prospective dose-escalation study.

and future studies are needed to clarify the molecular pathology of these diseases. Unfortunately, the prognoses of these malignancies are poor for both limited and advanced diseases, and new therapeutic modalities are needed to effectively treat patients. Appropriate therapeutic strategies should be explored in ongoing prospective studies.

ACKNOWLEDGMENTS

I would like to thank Drs. Kazuo Oshimi (Juntendo University School of Medicine) and Motoko Yamaguchi (Mie University School of Medicine) for critical reading of this manuscript.

References

- 1 The Non-Hodgkin's Lymphoma Pathologic Classification Project : National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas : Summary and description of Working Formulation for clinical usage. *Cancer* 49 : 2112-2135, 1982
- 2 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. *Blood* 84 : 1361-1392, 1994
- 3 Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszevska O, Wright DH : Updated Kiel classification for lymphomas. *Lancet* 1 : 292-293, 1988
- 4 Jaffe ES, Harris NL, Stein H, Vardiman JW eds. : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, IARC Pres, Lyon, 2001
- 5 Hercend T, Schmidt RE : Characteristics and uses of natural killer cells. *Immunol Today* 9 : 291-293, 1988
- 6 Robertson MJ, Ritz J : Biology and clinical relevance of human natural killer cells. *Blood* 76 : 2421-2438, 1990
- 7 Farag SS, VanDeusen JB, Feninger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. *Int J Hematol* 78 : 7-17, 2003
- 8 Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL. Phillips JH : Identification of a common T/natural killer cell progenitor in human fetal thymus. *J Exp Med* 180 : 569-576, 1994
- 9 Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H : Lymphokine requirement for the generation of natural killer cells from CD34⁺ hematopoietic progenitor cells. *Blood* 85 : 3538-3546, 1995
- 10 Fernandez LA, Pope B, Lee C, Zayed E : Aggressive natural killer cell leukemia in an adult and establishment of an NK cell line. *Blood* 67 : 925-930, 1986
- 11 Koizumi S, Seki H, Tachinami T, Taniguchi M, Matsuda A, Taga K, Nakarai T, Kato E, Taniguchi N, Nakamura H : Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7- surface phenotype : in vitro responsiveness of malignant cells to recombinant human interleukin 2. *Blood* 68 : 1065-1073, 1986
- 12 Imamura N, Kusunoki Y, Kawa-Ha K, Yunuma K, Hara J, Oda K, Abe K, Dohy H, Inada T, Kajihara H, Kuramoto A : Aggressive natural killer cell leukemia/lymphoma : Report of four cases and review of the literature. *Br J Haematol* 75 : 49-59, 1990
- 13 Loughran Jr. TP : Clonal diseases of large granular lymphocytes. *Blood* 82 : 1-14, 1993
- 14 Oshimi K, Yamada O, Kaneko T, Nishinarita S, Iizuka Y, Urabe A, Inamori T, Asano S, Takahashi S, Hattori M, Naohara T, Ohira Y, Togawa A, Masuda Y, Okubo Y, Furusawa S, Sakamoto S, Omine M, Mori M, Tatsumi E, Mizoguchi H : Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. *Leukemia* 7 : 782-788, 1993
- 15 Ishii Y, Yamanaka N, Ogawa K, Yoshida Y, Takami T, Matsuura A, Isago H, Kataura A, Kikuchi K : Nasal T-cell lymphoma as a type of so-called "lethal midline granuloma". *Cancer* 50 : 2336-2344, 1982
- 16 Stamenkovic I, Toccanier MF, Kapanci Y : Polymorphic reticulosis (lethal midline granuloma) and lymphomatoid granulomatosis : identical or distinct entities ? *Virchows Arch A Pathol Anat Histol* 390 : 81-91, 1981
- 17 Chan JKC, Ng CS, Ngan KC, Hui PK, Lo ST, Lau WH : Angiocentric T-cell lymphoma of the skin. An aggressive lymphoma distinct from mycosis fungoides. *Am J Surg Pathol* 12 : 861-876, 1988
- 18 Aviles A, Rodriguez L, Guzman R, Talavera A, Garcia EL, Diaz-Maqueo JC : Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. *Hematol Oncol* 10 : 141-147, 1992
- 19 Suzumiya J, Takeshita M, Kimura M, Kikuchi M, Uchida T, Hisano S, Eura Y, Kozuru M, Nomura Y, Tomita K, Komiyama S, Okumura M : Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. *Blood* 83 : 2255-2260, 1994
- 20 Jaffe ES, Chan JKC, Su I-J, Frizzera G, Mori S, Feller AC, Ho FC : Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. *Am J Surg Pathol* 20 : 103-111, 1996
- 21 Lymphoma Study Group of Japanese Pathologists : The World Health Organization classification of malignant lymphomas in Japan : Incidence of recently recognized entities. *Pathol Int* 50 : 696-702, 2000
- 22 Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, Gondo H, Hino N, Mori H, Sugimori H, Kawa K, Oshimi K and the NK-cell Tumor Study Group : Aggressive natural killer-cell leukemia revisited : large granular lymphocyte leukemia of cytotoxic NK cells. *Leukemia* 18 : 763-770, 2004
- 23 Chan JKC, Wong KF, Jaffe ES, Ralfkiaer E. Aggressive NK-cell leukemia. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours ; IARC Pres, Lyon, 198-200, 2001

- 24 Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F, Tawa A, Hirai K : CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. *J Clin Invest* 84 : 51-55, 1989
- 25 Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, Bongiovanni KF, Waldmann TA : Leukemia of non-T lineage natural killer cells. *Blood* 72 : 1701-1707, 1988
- 26 Taniwaki M, Tagawa S, Nishigaki H, Horiike S, Misawa S, Shimazaki C, Maekawa T, Fujii H, Kitani T, Abe T : Chromosomal abnormalities define clonal proliferation in CD3- large granular lymphocyte leukemia. *Am J Hematol* 33 : 32-38, 1990
- 27 Kwong YL, Wong KF, Chan LC, Liang RH, Chan JK, Lin CK, Chan TK : Large granular lymphocyte leukemia. A study of nine cases in a Chinese population. *Am J Clin Pathol* 103 : 76-81, 1995
- 28 Shimodaira S, Ishida F, Kobayashi H, Mahbub B, Kawa-Ha K, Kitano K : The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. *Br J Haematol* 90 : 578-584, 1995
- 29 Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH : Nonnasal lymphoma expressing the natural killer cell marker CD56 : a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. *Blood* 89 : 4501-4513, 1997
- 30 Mizuno S, Akashi K, Ohshima K, Iwasaki H, Miyamoto T, Uchida N, Shibuya T, Harada M, Kikuchi M, Niho Y : Interferon-gamma prevents apoptosis in Epstein-Barr virus-infected natural killer cell leukemia in an autocrine fashion. *Blood* 93 : 3494-3504, 1999
- 31 Akashi K, Mizuno S : Epstein-Barr virus-infected natural killer cell leukemia. *Leuk Lymphoma*. 40 : 57-66, 2000
- 32 Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K : Aggressive natural killer cell leukemia ; clinical features and treatment outcome. *Haematologica* 87 : 1343-1345, 2002
- 33 Ishihara S, Ohshima K, Tokura Y, Yabuta R, Imaishi H, Wakiuchi H, Kurashige T, Kishimoto H, Katayama I, Okada S, Kawa-Ha K : Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. *Jpn J Cancer Res* 88 : 82-87, 1997
- 34 Tokura Y, Ishihara S, Ohshima K, Hidano A, Koide M, Seo N, Takigawa M : Severe mosquito bite hypersensitivity, natural killer cell leukaemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. *Br J Dermatol* 138 : 905-906, 1998
- 35 Ishihara S, Yabuta R, Tokura Y, Ohshima K, Tagawa S : Hypersensitivity to mosquito bites is not an allergic disease, but an Epstein-Barr virus-associated lymphoproliferative disease. *Int J Hematol* 72 : 223-228, 2000
- 36 Soler J, Bordes R, Ortuno F, Montagud M, Martorell J, Pons C, Nomdedeu J, Lopez-Lopez JJ, Prat J, Rutllant M : Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. *Br J Haematol* 86 : 659-662, 1994
- 37 Pastan I, Gottesman M : Multidrug resistance in human cancer. *N Engl J Med* 316 : 1388-1393, 1987
- 38 Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M : Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. *Cancer* 76 : 2351-2356, 1995
- 39 Drénou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, Diebold J, Le Prise PY, Fauchet R. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. *Blood* 89 : 2966-2974, 1997
- 40 Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K : P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. *Blood* 93 : 599-606, 1999
- 41 Chan JKC, Jaffe ES, Ralfkiaer E : Extranodal NK/T-cell lymphoma, nasal type. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. *World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues*. IARC Press, Lyon, France, pp. 204-207, 2001
- 42 Oshimi K : Lymphoproliferative disorders of natural killer cells. *Int J Hematol* 63 : 279-290, 1996
- 43 Jaffe ES : Classification of natural killer (NK) cell and NK-like T-cell malignancies. *Blood* 87 : 1207-1210, 1996
- 44 Oshimi K : Leukemia and lymphoma of natural killer lineage cells. *Int J Hematol* 78 : 18-23, 2003
- 45 The Non-Hodgkin's Lymphoma Classification Project : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. *Blood* 89 : 3909-3918, 1997
- 46 Anderson JR, Armitage JO, Weisenburger DD : Epidemiology of the non-Hodgkin's lymphomas : distributions of the major subtypes differ by geographic locations. *Non-Hodgkin's Lymphoma Classification Project. Ann Oncol* 9 : 717-720, 1998
- 47 Au WY, Ma SY, Chim CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR : Clinicopathologic features and treatment outcome of mature T-cell and natural killer cell lymphomas diagnosed according to the World Health Organization classification scheme : a single center experience of ten years. *Ann Oncol* 16 : 206-214, 2005
- 48 Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR : REAL classification of malignant lymphomas in the Republic of Korea : incidence of recently recognized entities and changes in clinicopathologic features. *Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer* 83 : 806-812, 1998
- 49 Chen CY, Yao M, Tang JL, Tsay W, Wang CC, Chou WC, Su IJ, Lee FY, Liu MC, Tien HF : Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan : with special reference to T-cell lymphoma. *Ann Oncol* 15 : 1091-1096, 2004
- 50 Yamaguchi M, Ohno T, Oka K, Nishii K, Kawakami K, Miwa H, Kita K, Shirakawa S : Discordant reaction of Leu4 and rabbit anti-human CD3 epsilon in sinonasal T-cell lymphoma. *Int J Hematol* 59 : 25-30, 1993
- 51 Chan JKC, Tsang WY, Pau MY : Discordant CD3 expression in

- lymphomas when studied on frozen and paraffin sections. *Hum Pathol* 26 : 1139-1143, 1995
- 52 Emile J-F, Boulland M-L, Haioun C, Kanavaros P, Petrella T, Delfau-Larue MH, Bensussan A, Farcet JP, Gaulard P : CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. *Blood* 87 : 1466-1473, 1996
- 53 Mori N, Yatabe Y, Oka K, Kinoshita T, Kobayashi T, Ono T, Asai J : Expression of perforin in nasal lymphoma. Additional evidence of its natural killer cell derivation. *Am J Pathol* 149 : 699-705, 1996
- 54 Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE : TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. *Am J Pathol* 150 : 1893-1900, 1997
- 55 Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M, Kikuchi M : Nasal T/NK cell lymphomas commonly express perforin and Fas ligand : important mediators of tissue damage. *Histopathology* 31 : 444-450, 1997
- 56 Ng CS, Lo ST, Chan JK, Chan WC : CD56+ putative natural killer cell lymphomas : production of cytolytic effectors and related proteins mediating tumor cell apoptosis ? *Hum Pathol* 28 : 1276-1282, 1997
- 57 Boulland ML, Kanavaros P, Wechsler J, Casiraghi O, Gaulard P : Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. *J Pathol* 183 : 432-439, 1997
- 58 Yamashita Y, Yatabe Y, Tsuzuki T, Nakayama A, Hasegawa Y, Kojima H, Nagasawa T, Mori N : Perforin and granzyme expression in cytotoxic T-cell lymphomas. *Mod Pathol* 11 : 313-323, 1998
- 59 Krenacs L, Smyth MJ, Bagdi E, Krenacs T, Kopper L, Rudiger T, Zettl A, Muller-Hermelink HK, Jaffe ES, Raffeld M : The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas : evidence of origin from lymphocytes involved in innate immunity. *Blood* 101 : 3590-3593, 2003
- 60 Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, Nagata S, Kanatani Y, Wakimoto N, Nagata N, Motoyoshi K : An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. *Br J Haematol* 94 : 379-382, 1996
- 61 Kato K, Ohshima K, Ishihara S, Anzai K, Suzumiya J, Kikuchi M : Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. *Br J Haematol* 103 : 1164-1166, 1998
- 62 Mullauer L, Mosberger I, Chott A : Fas ligand expression in nodal non-Hodgkin's lymphoma. *Mod Pathol* 11 : 369-375, 1998
- 63 Haedicke W, Ho FC, Chott A, Moretta L, Rudiger T, Ott G, Muller-Hermelink HK : Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas. *Blood* 95 : 3628-3630, 2000
- 64 Hoffmann T, De Libero G, Colonna M, Wodnar-Filipowicz A, Passweg J, Favre G, Gratwohl A, Tichelli A : Natural killer-type receptors for HLA class I antigens are clonally expressed in lymphoproliferative disorders of natural killer and T-cell type. *Br J Haematol* 110 : 525-536, 2000
- 65 Dukers DF, Vermeer MH, Jaspars LH, Sander CA, Flaig MJ, Vos W, Willemze R, Meijer CJ : Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype. *J Clin Pathol* 54 : 224-228, 2001
- 66 Mori KL, Egashira M, Oshimi K : Differentiation stage of natural killer cell-lineage lymphoproliferative disorders based on phenotypic analysis. *Br J Haematol* 115 : 225-228, 2001
- 67 Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM : CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. *Blood* 102 : 2623-2631, 2003
- 68 Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T : Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. *Lancet* 335 : 128-130, 1990
- 69 Kanavaros P, Lescs MC, Briere J, Divine M, Galateau F, Joab I, Bosq J, Farcet JP, Reyes F, Gaulard P : Nasal T-cell lymphoma : a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. *Blood* 81 : 2688-2695, 1993
- 70 Chan JK, Yip TT, Tsang WY, Ng CS, Lau WH, Poon YF, Wong CC, Ma VW : Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. *Am J Surg Pathol* 18 : 938-946, 1994
- 71 Wong KF, Chan JK, Kwong YL : Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. *Br J Haematol* 98 : 922-926, 1997
- 72 Tien HF, Su IJ, Tang JL, Liu MC, Lee FY, Chen YC, Chuang SM : Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. *Br J Haematol* 97 : 621-625, 1997
- 73 Gaidano G, Hauptschein RS, Parsa NZ, Offit K, Rao PH, Lenoir G, Knowles DM, Chaganti RS, Dalla-Favera R : Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. *Blood* 80 : 1781-1787, 1992
- 74 Merup M, Moreno TC, Heyman M, Ronnberg K, Grander D, Detlofsson R, Rasool O, Liu Y, Soderhall S, Juliusson G, Gahrton G, Einhorn S : 6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. *Blood* 91 : 3397-3400, 1998
- 75 Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, Choy D, Ho FC : Treatment outcome and prognostic factors for primary nasal lymphoma. *J Clin Oncol* 13 : 666-670, 1995
- 76 Kwong YL, Chan ACL, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC : CD56+ NK lymphomas : clinicopathological features and prognosis. *Br J Haematol* 97 : 821-829, 1997
- 77 Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD : Lymphoma of the nasal cavity and paranasal sinuses : improved outcome and altered prognostic factors with combined modality therapy. *Cancer* 80 : 477-488, 1997
- 78 Cheung MMC, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK : Primary non-Hodgkin's lymphoma of the nose and nasopharynx : clinical features, tumor immunophenotype, and treatment outcome in 113 patients. *J Clin Oncol* 16 : 70-77, 1998

- 79 Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW : Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. *Cancer* 89 : 2106-2116, 2000
- 80 Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL : Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. *Cancer* 100 : 366-375, 2004
- 81 Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL : Primary nasal natural killer cell lymphoma : long-term treatment outcome and relationship with the international prognostic index. *Blood* 103 : 216-221, 2004
- 82 You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, Hsu HC, Gau JP, Tzeng CH, Liu JH, Chen PM, Chiou TJ : Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma : a single institute survey in Taiwan. *Ann Oncol* 15 : 618-625, 2004
- 83 Kern WF, Spier CM, Hannneman EH, Miller TP, MatznerM, Grogan TM : Neural cell adhesion molecule-positive peripheral T-cell lymphoma : a rare variant with a propensity for unusual sites of involvement. *Blood* 79 : 2432-2437, 1992
- 84 Wong KF, Chan JKC, Ng CS, Lee KC, Tsang WYW, Cheung MMC : CD56 (NKH1)-positive hematolymphoid malignancies : an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. *Hum Pathol* 23 : 798-804, 1992
- 85 Rodriguez J, Romaguera JE, Manning J, Ordonez N, Ha C, Ravan-di F, Cabanillas F : Nasal-type T/NK lymphomas : a clinico-pathologic study of 13 cases. *Leuk Lymphoma* 39 : 139-144, 2000
- 86 Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH : Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin : an increasingly recognized entity with an aggressive course. *J Clin Oncol* 19 : 2179-2188, 2001
- 87 Santucci M, Pimpinelli N, Massi D, Kadin ME, Meijer CJ, Muller-Hermelink HK, Paulli M, Wechsler J, Willemze R, Audring H, Bernengo MG, Cerroni L, Chimenti S, Chott A, Diaz-Perez JL, Dippel E, Duncan LM, Feller AC, Geerts ML, Hallermann C, Kempf W, Russell-Jones R, Sander C, Berti E for the EORTC Cutaneous Lymphoma Task Force : Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. *Cancer* 97 : 610-627, 2003
- 88 Massone C, Chott A, Metze D, Kerl K, Citarella L, Vale E, Kerl H, Cerroni L : Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin : a morphologic, immunophenotypic, and molecular study of 50 patients. *Am J Surg Pathol* 28 : 719-735, 2004
- 89 Bekkenk MW, Jansen PM, Meijer CJ, Willemze R : CD56+ hematological neoplasms presenting in the skin : a retrospective analysis of 23 new cases and 130 cases from the literature. *Ann Oncol* 15 : 1097-1108, 2004
- 90 Ko YH, Cho EY, Kim JE, Lee SS, Huh JR, Chang HK, Yang WI, Kim CW, Kim SW, Ree HJ : NK and NK-like T-cell lymphoma in extranasal sites : a comparative clinicopathological study according to site and EBV status. *Histopathology* 44 : 480-489, 2004
- 91 Chim CS, Ma ES, Loong F, Kwong YL : Diagnostic cues for natural killer cell lymphoma : primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement. *J Clin Pathol* 58 : 443-445, 2005
- 92 Yu KH, Yu SC, Teo PM, Chan AT, Yeo W, Chow J : Nasal lymphoma : results of local radiotherapy with or without chemotherapy. *Head Neck* 19 : 251-259, 1997
- 93 Shikama N, Izuno I, Oguchi M, Gomi K, Sone S, Takei K, Sasaki S, Wako T, Itou N, Ishii K : Clinical stage IE primary lymphoma of the nasal cavity : radiation therapy and chemotherapy. *Radiology* 204 : 467-470, 1997
- 94 Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ, Mirimanoff RO, Yu ZH, Huang YR : Primary non-Hodgkin's lymphoma of the nasal cavity : prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. *Cancer* 83 : 449-456, 1998
- 95 Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK, Kim BS : Angiocentric lymphoma of the head and neck : patterns of systemic failure after radiation treatment. *J Clin Oncol* 18 : 54-63, 2000
- 96 Aviles A, Diaz NR, Neri N, Cleto S, Talavera A : Angiocentric nasal T/natural killer cell lymphoma : a single centre study of prognostic factors in 108 patients. *Clin Lab Haematol* 22 : 215-220, 2000
- 97 Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K : CHOP followed by involved field radiation : is it optimal for localized nasal natural killer/T-cell lymphoma ? *Ann Oncol* 12 : 349-352, 2001
- 98 Ribrag V, Ell Hajj M, Janot F, Girinsky T, Domenge C, Schwaab G, Fenaux P, Bosq J : Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. *Leukemia* 15 : 1123-1126, 2001
- 99 Shikama N, Ikeda H, Nakamura S, Oguchi M, Isobe K, Hirota S, Hasegawa M, Nakamura K, Sasai K, Hayabuchi N : Localized aggressive non-Hodgkin's lymphoma of the nasal cavity : a survey by the Japan Lymphoma Radiation Therapy Group. *Int J Radiat Oncol Biol Phys* 51 : 1228-1233, 2001
- 100 Yamaguchi M, Ogawa S, Nomoto Y, Oka K, Taniguchi M, Nakase K, Kobayashi T, Shiku H : Treatment outcome of nasal NK-cell lymphoma : A report of 12 consecutively-diagnosed cases and a review of the literature. *J Clin Exp Hematopathol* 41 : 93-99, 2001
- 101 Cheung MMC, Chan JKC, Lau W-H, Ngan RK, Foo WW : Early stage nasal NK/T-cell lymphoma : clinical outcome, prognostic factor, and the effect of treatment modality. *Int J Radiat Oncol Biol Phys* 54 : 182-190, 2002
- 102 Nakamura S, Suchi T, Koshikawa T, Kitoh K, Koike K, Komatsu H, Iida S, Kagami Y, Ogura M, Katoh E, Kurita S, Suzuki H,

- Kobayashi Y, Yamabe H, Hirabayashi N, Ueda R, Takahashi T : Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. *Am J Surg Pathol* 19 : 284-296, 1995
- 103 DiGiuseppe JA, Louie DC, Williams JE, Miller DT, Griffin CA, Mann RB, Borowitz MJ : Blastic natural killer cell leukemia/lymphoma : A clinicopathologic study. *Am J Surg Pathol* 21 : 1223-1230, 1997
- 104 Suzuki R, Nakamura S : Malignancies of natural killer (NK) cell precursor : myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. *Leuk Res* 23 : 615-624, 1999
- 105 Chan JKC, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In : Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). *World Health Organization Classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon : IARC Press, 2001, pp 214-215.
- 106 Falcao RP, Garcia AB, Marques MG, Simoes BP, Fonseca BA, Rodrigues ML Foss NT : Blastic CD4 NK cell leukemia/lymphoma : a distinct clinical entity. *Leuk Res* 26 : 803-807, 2002
- 107 Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D. CD56⁺ TdT⁺ blastic natural killer cell tumor of the skin : a primitive systemic malignancy related to myelomonocytic leukemia. *Cancer* 94 : 2401-2408, 2002
- 108 Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, Muller-Hermelink HK, Wilhelm M : What is CD4+ CD56+ malignancy and how should it be treated ? *Bone Marrow Transplant* 32 : 637-646, 2003
- 109 Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Suefuji H, Suzumiya J, Harada M, Kikuchi M : Non-B, non-T neoplasms with lymphoblast morphology : further clarification and classification. *Am J Surg Pathol* 27 : 1366-1374, 2003
- 110 Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, Kura Y, Aikawa K, Teshima H, Sako M, Kojima H, Nishio M, Yoshino T, Sugimori H, Kawa K, Oshimi K for the NK-cell Tumor Study Group : Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor) : prognostication and categorization according to anatomic sites of involvement. *Cancer* 104 : 1022-1031, 2005
- 111 Pirruccello SJ, Bicak MS, Gordon BG, Gajl-Peczalska K, Gnarr DJ, Coccia PF : Acute lymphoblastic leukemia of NK-cell lineage : Response to IL-2. *Leuk Res* 13, 735-743, 1989
- 112 Ichikawa M, Kawai H, Komiyama A, Tsudo M, Miyasaka M, Kinoshita A, Nakazawa S : Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties. *Am J Hematol* 36 : 259-264, 1991
- 113 Brody JP, Allen S, Schulman P, Sun T, Chan WC, Friedman HD, Teichberg S, Koduru P, Cone RW, Loughran Jr TP : Acute agranular CD4-positive natural killer cell leukemia. *Cancer* 75 : 2474-2483, 1994
- 114 Gardiner CM, Reen DJ, O'Meara A : Recognition of unusual presentation of natural killer cell leukemia. *Am J Hematol* 50 : 133-139, 1995
- 115 Nakamura F, Tatsumi E, Kawano S, Tani A, Kumagai S, Nishikori M, Nagai T : Acute lymphoblastic leukemia/lymphoblastic lymphoma of natural killer (NK) lineage : quest for another NK-lineage neoplasm. *Blood* 89 : 4665-4666, 1997
- 116 Shinoda K, Muraki T, Yano M, Yamada T, Takao A : Infant leukemia suggestive of natural killer cell precursor origin followed an unusual clinical course. *Acta Haematol* 104 : 202-206, 2000
- 117 Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Briere F, Plumas J, Jacob MC : Identification of a leukemic counterpart of the plasmacytoid dendritic cells. *Blood* 97 : 3210-3217, 2001
- 118 Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Bene MC : Clinical and biologic features of CD4+ CD56+ malignancies. *Blood* 99 : 1556-1563, 2002
- 119 Petrella T, Comeau MR, Maynadie M, Couillault G, De Muret A, Maliszewski CR, Dalac S, Durlach A, Galibert L : Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. *Am J Surg Pathol* 26 : 852-862, 2002
- 120 O'Doherty U, Steinman RM, Peng M, Cameron PU, Gezelter S, Kopeloff I, Swiggard WJ, Pope M, Bhardwaj N : Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. *J Exp Med* 178 : 1067-1076, 1993
- 121 Vandenabeele S, Hochrein H, Mavaddat N, Winkel K, Shortman K : Human thymus contains 2 distinct dendritic cell populations. *Blood* 97 : 1733-1741, 2001
- 122 MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ : Characterization of human blood dendritic cell subsets. *Blood* 100 : 4512-4520, 2002
- 123 Comeau MR, Van der Vuurst de Vries A-R, Maliszewski CR, Galibert L : CD123 bright plasmacytoid predendritic cells : progenitors undergoing cell fate conversion ? *J Immunol* 169 : 75-83, 2002
- 124 Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J, Miyajima A : Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. *Blood* 82 : 752-761, 1993
- 125 Miyajima A, Mui AL, Ogorochi T, Sakamaki K : Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. *Blood* 82 : 1960-1974, 1993
- 126 Momoi A, Toba K, Kawai K, Tsuchiyama J, Suzuki N, Yano T, Uesugi Y, Takahashi M, Aizawa Y : Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin : two cases. *Leuk Res* 26 : 693-698, 2002

- 127 Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadie M, Machet L, Casasnovas O, Vergier B, Teitell MA : TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. *Am J Clin Pathol* 122 : 307-313, 2004
- 128 Suzuki R, Yamamoto K, Seto M, Kagami Y, Ogura M, Yatabe Y, Suchi T, Kodera Y, Morishima Y, Takahashi T, Saito H, Ueda R, Nakamura S : CD7⁺ and CD56⁺ myeloid/natural killer cell precursor acute leukemia : A distinct hematolymphoid disease entity. *Blood* 90 : 2417-2428, 1997
- 129 Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C : Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). *Br J Haematol* 78 : 325-329, 1991
- 130 Béné M-C, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matutes E, Orfao A, Schoch C, Sperling C, van't Veer MB : Acute myeloid leukaemia M0 : haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance : an analysis in 241 patients. *Br J Haematol* 113 : 737-745, 2001
- 131 Scott AA, Head DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, Chen IM, Whittaker MH, Griffith BB, Licht JD, Waxman S, Whalen MM, Bankhurst AD, Richter LC, Grogan TM, Willman CL : HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia : a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. *Blood* 84 : 244-253, 1994
- 132 Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y, Tomonaga M, Masaki Y, Kusumoto S, Takeuchi J, Matsuda S, Hirai H, Yorimitsu S, Hamajima N, Seto M, Shimoyama M, Ohno R, Morishima Y, Nakamura S : Prognostic significance of CD7+ CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. *Int J Hematol* 77 : 482-489, 2003
- 133 Oshimi K, Kawa K, Nakamura S, Suzuki R, Suzumiya J, Yamaguchi M, Kameoka J, Tagawa S, Imamura N, Ohshima K, Kojima S, Iwatsuki K, Tokura Y, Sato E, Sugimori H : NK-cell Tumor Study Group. NK-cell neoplasms in Japan. *Hematology J* 10 : 237-245, 2005
- 134 Kuerbitz SJ, Civin CI, Krischer JP, Ravindranath Y, Steuber CP, Weinsein HJ, Winick N, Ragab AH, Gresik MV, Crist WM : Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood : A pediatric oncology group study. *J Clin Oncol* 10 : 1419-1429, 1992
- 135 Vidriales MB, Orfao A, Gonzalez M, Hernandez JM, Lopez-Berges MC, Garcia MA, Canizo MC, Caballero MD, Macedo A, Landolfi C : Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. *Leukemia* 7 : 2026-2029, 1993
- 136 Seymour JF, Pierce SA, Kantarjian HM, Keating MI, Estey EH : Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). *Leukemia* 8 : 823-826, 1994
- 137 Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F : CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. *Leukemia* 15 : 1161-1164, 2001
- 138 Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A, Masolini P, Michelutti A, Geromin A, Fanin R, Lauria F : CD56 and PGP expression in acute myeloid leukemia : impact on clinical outcome. *Haematologica* 87 : 1135-1140, 2002
- 139 Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD : Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. *Leuk Res* 28 : 43-48, 2004
- 140 Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD : Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). *Blood* 90 : 1643-1648, 1997
- 141 Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC : CD56 expression in acute promyelocytic leukemia : a possible indicator of poor treatment outcome ? *J Clin Oncol* 17 : 293-297, 1999
- 142 Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F : CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. *J Clin Oncol* 18 : 1295-1300, 2000
- 143 Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F : Prognostic significance of CD56 antigen expression in acute myeloid leukemia. *Haematologica* 87 : 250-256, 2002
- 144 Ito S, Ishida Y, Oyake T, Satoh M, Aoki Y, Kowata S, Uchiyama T, Enomoto S, Sugawara T, Numaoka H, Suzuki K, Murai K : Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. *Leuk Lymphoma* 45 : 1783-1789, 2004
- 145 Thomas X, Vila L, Campos L, Sabido O, Archimbaud E : Expression of N-CAM (CD56) on acute leukemia cells : relationship with disease characteristics and outcome. *Leuk Lymphoma* 19 : 295-300, 1995
- 146 Paietta E, Neuberger D, Richards S, Bennett JM, Han L, Racevskis J, Dewald G, Rowe JM, Wiernik PH : Eastern Cooperative Oncology Group. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. *Am J Hematol* 66 : 189-196, 2001
- 147 Pombo-de-Oliveira MS, Campos MM, Bossa YE, Alencar DM, Curvello C, Agudelo DP, Mendonca N, Pereira E, Macedo-Silva ML : Acute leukemia with natural killer cells antigens in Brazi-

- lian children. *Leuk Lymphoma* 45 : 739-743, 2004
- 148 Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, Raffeld M : Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease : evidence for distinct cellular origin. *Blood* 89 : 980-989, 1997
- 149 Arnulf B, Copie-Bergman C, Delfau-Larue MH, Lavergne-Slove A, Bosq J, Wechsler J, Wassef M, Matuchansky C, Epardeau B, Stern M, Bagot M, Reyes F, Gaulard P : Nonhepatosplenic gammadelta T-cell lymphoma : a subset of cytotoxic lymphomas with mucosal or skin localization. *Blood* 91 : 1723-1731, 1998
- 150 Chott A, Haedicke W, Mosberger I, Fodinger M, Winkler K, Mannhalter C, Muller-Hermelink HK : Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. *Am J Pathol* 153 : 1483-1490, 1998
- 151 Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC : The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL) : correlation with morphology, immunophenotype, ultrastructure, and clinical features. *Hum Pathol* 30 : 228-236, 1999
- 152 Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. *Blood* 96 : 2993-3000, 2000
- 153 Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, Morishima Y, Takeuchi K, Nakamura S : Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. *Am J Surg Pathol* 29 : 1284-1293, 2005
- 154 Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JB : Natural killer-like T-cell lymphomas : aggressive lymphomas of T-large granular lymphocytes. *Blood* 87 : 1474-1483, 1996
- 155 Mraz-Gemhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH : Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin : an increasingly recognized entity with an aggressive course. *J Clin Oncol* 19 : 2179-2188, 2001
- 156 Ralfkiaer E, Muller-Hermelink HK, Jaffe ES : Peripheral T-cell lymphoma, unspecified. In *World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues* (edited by Jaffe ES, Harris NL, Stein H, Vardiman JW), IARC Press, Lyon, France, p. 227-229, 2001
- 157 Ohno T, Yamaguchi M, Oka K, Miwa H, Kita K, Shirakawa S : Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. *Leukemia* 9 : 44-52, 1995.
- 158 Weidmann E : Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. *Leukemia* 14 : 991-997, 2000
- 159 Macon WR, Levy NB, Kurtin PJ, Salhany KE, Elkhaila MY, Casey TT, Craig FE, Vnencak-Jones CL, Gulley ML, Park JP, Cousar JB : Hepatosplenic $\alpha\beta$ T-cell lymphomas : a report of 14 cases and comparison with hepatosplenic $\gamma\delta$ T-cell lymphomas. *Am J Surg Pathol* 25 : 285-296, 2001
- 160 Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R, Deconinck E, Charlotte F, Leblond V, Labouyrie E, Lederlin P, Emile JF, Delmas-Marsalet B, Arnulf B, Zafrani ES, Gaulard P : Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome : report on a series of 21 patients. *Blood* 102 : 4261-4269, 2003
- 161 Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH : Enteropathy-type intestinal T-cell lymphoma : clinical features and treatment of 31 patients in a single center. *J Clin Oncol* 18 : 795-803, 2000
- 162 Garin-Chesa P, Fellingner EJ, Huvos AG, Beresford HR, Melamed MR, Triche TJ, Rettig WJ : Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence. *Am J Pathol* 139 : 275-286, 1991
- 163 Mechtersheimer G, Staudter M, Moller P : Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. *Cancer Res* 51 : 1300-1307, 1991
- 164 Roth J, Blaha I, Bitter-Suermann D, Heitz PU : Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution. *Am J Pathol* 133 : 596-608, 1988
- 165 Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU : Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. *Am J Pathol* 139 : 297-304, 1991
- 166 Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad O : Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. *Am J Pathol* 141 : 531-538, 1992
- 167 Ohshima K, Haraoka S, Ishihara S, Ohgami A, Yoshioka S, Suzumiya J, Kikuchi M : Analysis of chromosome 6q deletion in EBV-associated NK cell leukemia/lymphoma. *Leuk Lymphoma* 43 : 293-300, 2002
- 168 Sun HS, Su I-J, Lin Y-C, Chen J-S, Fang S-Y : A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. *Br J Haematol* 122 : 590-599, 2003
- 169 Yoon J, Ko YH : Deletion mapping of the long arm of chromosome 6 in peripheral T and NK cell lymphomas. *Leuk Lymphoma* 44 : 2077-2082, 2003
- 170 Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. *Jpn J Cancer Res* 92 : 1048-1056, 2001
- 171 Sugimoto KJ, Kawamata N, Sakajiri S, Oshimi K. Molecular

- analysis of oncogenes, ras family genes (N-ras, K-ras, H-ras), myc family genes (c-myc, N-myc) and mdm2 in natural killer cell neoplasms. *Jpn J Cancer Res* 93 : 1270-1277, 2002
- 172 Takakuwa T, Dong Z, Nakatsuka S, Kojya S, Harabuchi Y, Yang WI, Nagata S, Aozasa K : Frequent mutations of Fas gene in nasal NK/T cell lymphoma. *Oncogene* 21 : 4702-4705, 2002
- 173 Shen L, Liang AC, Lu L, Au WY, Kwong YL, Liang RH, Srivastava G : Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. *Am J Pathol* 161 : 2123-2131, 2002
- 174 Siu LL, Chan JK, Wong KF, Kwong YL : Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved. *Am J Pathol* 160 : 59-66, 2002
- 175 Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T : Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. *Cancer Res* 62 : 6390-6394, 2002
- 176 Siu LL, Chan JK, Wong KF, Choy C, Kwong YL : Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. *Br J Haematol* 122 : 70-77, 2003
- 177 Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y : P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. *Hum Pathol* 35 : 86-95, 2004
- 178 Hoshida Y, Hongyo T, Jia X, He Y, Hasui K, Dong Z, Luo WJ, Ham MF, Nomura T, Aozasa K : Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. *Cancer Sci* 94 : 297-301, 2003
- 179 Hongyo T, Hoshida Y, Nakatsuka S, Syaifudin M, Kojya S, Yang WI, Min YH, Chan H, Kim CH, Harabuchi Y, Himi T, Inuyama M, Aozasa K, Nomura T : p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan. *Oncol Report* 13 : 265-271, 2005
- 180 Kawamata N, Inagaki N, Mizumura S, Sugimoto KJ, Sakajiri S, Ohyanagi-Hara M, Oshimi K : Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. *Eur J Haematol* 74 : 424-429, 2005
- 181 Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L, Cabras A, Hoefler H, Mohar A, Fend F : p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico : association with large cell morphology and advanced disease. *Am J Pathol* 159 : 2095-2105, 2001
- 182 Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K, Nomura T : Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. *Cancer Res* 60 : 2345-2347, 2000
- 183 Siu LL, Wong KF, Chan JK, Kwong YL : Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. *Am J Pathol* 155 : 1419-1425, 1999
- 184 Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL : Consistent patterns of allelic loss in natural killer cell lymphoma. *Am J Pathol* 157 : 1803-1809, 2000
- 185 Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, Takahashi K, Tsuchiyama J, Akagi T : Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray. *Am J Pathol* 159 : 1495-1505, 2001
- 186 Ko YH, Choi KE, Han JH, Kim JM, Ree HJ : Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma. *Cytometry* 46 : 85-91, 2001.
- 187 Nakashima Y, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, Muta K, Nawata H, Morishima Y, Nakamura S, Seto M : Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia : Different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. *Genes Chromosomes Cancer* 44 : 247-255, 2005
- 188 Quintanilla-Martinez L, Jaffe ES : Aggressive NK cell lymphomas : insights into the spectrum of NK cell derived malignancies. *Histopathology* 37 : 372-374, 2000
- 189 Hart DNJ, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E, Rowe M, Beard MEJ : Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. *Blood* 79 : 2116-2123, 1992
- 190 Kawa K : Epstein-Barr virus—associated diseases in humans. *Int J Hematol* 71 : 108-117, 2000
- 191 Chiang AK, Tao Q, Srivastava G, Ho FC : Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. *Int J Cancer* 68 : 285-290, 1996
- 192 Kawa K : Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease. *Int J Hematol* 78 : 24-31, 2003
- 193 Tanner J, Weis J, Fearon D, Whang Y, Kieff E : Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. *Cell* 50 : 203-213, 1987
- 194 Kaneko T, Fukuda J, Yoshihara T, Zheng H, Mori S, Mizoguchi H, Oshimi K : Nasal natural killer (NK) cell lymphoma : report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. *Br J Haematol* 91 : 355-361, 1995
- 195 Yoshiyama H, Imai S, Shimizu N, Takada K : Epstein-Barr virus infection of human gastric carcinoma cells : implication of the existence of a new virus receptor different from CD21. *J Virol* 71 : 5688-5691, 1997
- 196 Isobe Y, Sugimoto K, Yang L, Tamayose K, Egashira M, Kane-

- ko T, Takada K, Oshimi K : Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. *Cancer Res* 64 : 2167-2174, 2004
- 197 Hammerschmidt W, Sugden B : Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. *Nature* 340 : 393-397, 1989
- 198 Ohshima K, Suzumiya J, Kanda M, Kato A, Kikuchi M : Integrated and episomal forms of Epstein-Barr virus (EBV) in EBV associated disease. *Cancer Lett* 122 : 43-50, 1998
- 199 Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, Kobayashi T, Tsurumi T, Seto M, Ogura M, Taguchi O, Morishima Y : Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2⁺, sCD3⁻, CD3 ϵ ⁺, CD56⁺ phenotype and associated with the Epstein-Barr virus. *Br J Haematol* 103 : 669-677, 1998
- 200 Nagata H, Numata T, Konno A, Mikata I, Kurasawa K, Hara S, Nishimura M, Yamamoto K, Shimizu N : Presence of natural killer-cell clones with variable proliferative capacity in chronic active Epstein-Barr virus infection. *Pathol Int* 51 : 778-785, 2001
- 201 Suzuki K, Ohshima K, Karube K, Suzumiya J, Ohga S, Ishihara S, Tamura K, Kikuchi M : Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. *Int J Oncol* 24 : 1165-1174, 2004
- 202 Mutirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguansinchi P, Yenrudi S, Voravud N, Supiyaphun P, Poovorawan Y : Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin Cancer Res* 4 : 665-669, 1998
- 203 Lei KIK, Chan LYS, Chan W-Y, Johnson PJ, Dennis Lo YM : Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. *Clin Cancer Res* 8 : 29-34, 2002
- 204 Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung S-F, Chan LYS, Chow KCK, Lo YMD : Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. *Cancer Res* 63 : 2028-2032, 2003
- 205 Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT : Severe chronic active Epstein-Barr virus infection syndrome. *Clin Microbiol Rev* 4 : 129-135, 1991
- 206 Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, Todo S, Green M : Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. *J Clin Microbiol* 35 : 1612-1615, 1997
- 207 Stevens SJC, Pronk I, Middeldorp JM : Toward standardization of Epstein-Barr virus DNA load monitoring : unfractionated whole blood as preferred clinical specimen. *J Clin Microbiol* 39 : 1211-1216, 2001
- 208 Wadowsky RM, Laus S, Green M, Webber SA, Rowe D : Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. *J Clin Microbiol* 41 : 5245-5249, 2003
- 209 Drexler HG, Matsuo Y : Malignant hematopoietic cell lines : in vitro models for the study of natural killer cell leukemia-lymphoma. *Leukemia* 14 : 777-782, 2000
- 210 Matsuo Y, Drexler HG : Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. *Leuk Res* 27 : 935-945, 2003
- 211 Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, Uchiyama T, Maeda M : TCGF (IL 2)-receptor inducing factor (s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). *J Immunol* 134 : 1623-1630, 1985
- 212 Gong JH, Maki G, Klingemann HG : Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. *Leukemia* 8 : 652-658, 1994
- 213 Kojima H, Suzukawa K, Yatabe Y, Hori M, Nagasawa T, Abe T : Establishment of a new natural killer (NK) cell line, TKS-1, from a patient with aggressive type of large granular lymphocyte (LGL) leukemia. *Leukemia* 8 : 1999-2004, 1994
- 214 Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J : Characterization of a cell line, NK1, derived from an aggressive human natural killer cell leukemia. *Exp Hematol* 24 : 406-415, 1996
- 215 Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, Hiraki A, Nakayama H, Shibuya A, Ma Y, Kawabata T, Okada S, Harada M : Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. *Blood* 92 : 1374-1383, 1998
- 216 Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H : Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy ; establishment of an IL-2-dependent NK-like cell line. *Clin Exp Immunol* 115 : 385-392, 1999
- 217 Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K : A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. *Leukemia* 14 : 922-930, 2000
- 218 Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, Sekine T, Yamamoto K, Shimizu N : Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. *Blood* 97 : 708-713, 2001
- 219 Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, Demachi A, Morio T, Wakiguchi H, Kimura N, Shimizu N, Yamamoto K : Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. *Br*

- J Haematol 121 : 805-814, 2003
- 220 Chen IM, Whalen M, Bankhurst A, Sever CE, Doshi R, Hardekopf D, Montgomery K, Willman CL : A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping : functional and cytogenetic characterization. *Leuk Res* 28 : 275-284, 2004
- 221 Hellmann D, Cowan MJ, Ammann AJ, Wara DW, Chudwin D, Chang RS : Chronic active Epstein-Barr virus infections in two immunodeficient patients. *J Pediatr* 103 : 585-588, 1983
- 222 Rickinson AB : Chronic, symptomatic Epstein-Barr virus infection. *Immunol Today* 7 : 13-14, 1986
- 223 Kawa-Ha K, Franco E, Doi S, Yumura K, Ishihara S, Tawa A, Yabuuchi H : Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. *Lancet* 1 : 154, 1987
- 224 Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES : Fulminant EBV (+) T-cell lymphoproliferative disorder following acute/chronic EBV infection : a distinct clinicopathologic syndrome. *Blood* 96 : 443-451, 2000
- 225 Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S : Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. *J Clin Oncol* 19 : 2665-2673, 2001
- 226 Kawa K, Okamura T, Yasui M, Sato E, Inoue M : Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. *Crit Rev Oncol Hematol* 44 : 251-257, 2002
- 227 Ha SY, Chung CW, Ko YH : Severe chronic active EBV infection in an adult patient : case report. *J Korean Med Sci* 19 : 453-457, 2004
- 228 Tefferi A, Li C-Y, Witzig TE, Dhodapkar MV, Okuno SH, Philyly RL : Chronic natural killer cell lymphocytosis : a descriptive clinical study. *Blood* 84 : 2721-2725, 1994
- 229 Rabbani GR, Philyly RL, Tefferi A : A long-term study of patients with chronic natural killer cell lymphocytosis. *Br J Haematol* 106 : 960-966, 1999
- 230 Ohno Y, Amakawa R, Fukuhara S, Huang CR, Kamesaki H, Amano H, Imanaka T, Takahashi Y, Arita Y, Uchiyama T, Kita K, Miwa H : Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality. *Cancer* 64 : 63-67, 1989
- 231 Tagawa S, Mizuki M, Onoi U, Nakamura Y, Nozima J, Yoshida H, Kondo K, Mukai T, Yamanishi K, Kitani T : Transformation of large granular lymphocytic leukemia during the course of a reactivated human herpesvirus-6 infection. *Leukemia* 6 : 465-469, 1992
- 232 Matsubara A, Matsumoto M, Takada K, Hato T, Hasegawa H, Tamai T, Yasukawa M, Fujita S : Acute transformation of chronic large granular lymphocyte leukemia into an aggressive form associated with preferential organ involvement. *Acta Haematol* 91 : 206-210, 1994
- 233 Loughran TP Jr, Zambello R, Ashley R, Guderian J, Pellenz M, Semenzato G, Starkebaum G : Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. *Blood* 81 : 2723-2727, 1993
- 234 Loughran TP Jr, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Fong SK, Poiesz BJ : Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. *Blood* 90 : 1977-1981, 1997
- 235 Perzova RN, Loughran TP, Dube S, Ferrer J, Esteban E, Poiesz BJ : Lack of BLV and PTLV DNA sequences in the majority of patients with large granular lymphocyte leukaemia. *Br J Haematol* 109 : 64-70, 2000
- 236 Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. *N Engl J Med* 339 : 21-26, 1998
- 237 Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH : Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma : Eastern Cooperative Oncology Group study 1484. *J Clin Oncol* 22 : 3032-3038, 2004
- 238 Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. *J Clin Oncol* 17 : 2915-2921, 1999
- 239 Pignon JP, Bourhis J, Domenge C, Designe L : Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma : Three meta-analyses of updated individual data ? MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. *Lancet* 355 : 949-955, 2000
- 240 Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 17 : 2692-2699, 1999
- 241 Teshima T, Miyaji R, Fukuda M, Ohshima K : Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. *Lancet* 347 : 1124, 1996
- 242 Liang R, Chen F, Lee CK, Kwong YL, Chim CS, Yau CC, Chiu E : Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. *Bone Marrow Transplant* 19 : 91-93, 1997
- 243 Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y, Sugimori N, Zeng W, Wang H, Kotani T, Shiobara S, Matsuda T : Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant* 21 : 1279-1282, 1998

- 244 Nawa Y, Takenaka K, Shinagawa K, Deguchi S, Matsumura N, Koyama S, Hiramatsu Y, Omoto E, Yoshino T, Harada M : Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant* 23 : 1321-1322, 1999
- 245 Sasaki M, Matsue K, Takeuchi M, Mitome M, Hirose Y : Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous peripheral blood stem cell transplantation. *Int J Hematol* 71 : 75-78, 2000
- 246 Nagafuji K, Fujisaki T, Arima F, Ohshima K : L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. *Int J Hematol* 74 : 447-450, 2001
- 247 Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, Yamamoto K, Fujii N, Nawa Y, Hiramatsu Y, Sunami K, Ishimaru F, Yoshino T, Kiura K, Harada M : High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. *Leuk Lymphoma* 42 : 1297-1303, 2001
- 248 Sanda T, Iida S, Ito M, Tsuboi K, Miura K, Harada S, Komatsu H, Wakita A, Inagaki H, Ueda R : Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy. *Int J Hematol* 75 : 195-200, 2002
- 249 Makita M, Maeda Y, Takenaka K, Shinagawa K, Sunami K, Hiramatsu Y, Fujii N, Ishimaru F, Ikeda K, Niiya K, Yoshino T, Harada M : Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. *Int J Hematol* 76 : 94-97, 2002
- 250 Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK : Autologous stem cell transplantation for nasal NK/T-cell lymphoma : a progress report on its value. *Ann Oncol* 14 : 1673-1676, 2003
- 251 Izutsu K, Kanda Y, Ohno H, Sao H, Ogawa H, Miyazaki Y, Kawa K, Kadera Y, Kato S, Morishima Y, Hirai H : Unrelated bone marrow transplantation for non-Hodgkin lymphoma : a study from the Japan Marrow Donor Program. *Blood* 103 : 1955-1960, 2004
- 252 Murashige N, Kami M, Kishi Y, Kim S-W, Takeuchi M, Matsue K, Kanda Y, Hirokawa M, Kawabata Y, Matsumura T, Kusumi E, Hirabayashi N, Nagafuji K, Suzuki R, Takeuchi K, Oshimi K : Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. *Br J Haematol* 130 : 561-567, 2005
- 253 Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ : Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. *Med Oncol* 20 : 13-17, 2003
- 254 Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J : L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. *Int J Hematol* 78 : 163-167, 2003
- 255 Obama K, Tara M, Niina K : L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. *Int J Hematol* 78 : 248-250, 2003
- 256 Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, Horiike S, Yokota S, Kusuzaki K, Kitoh T, Watanabe A, Taniwaki M : Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. *Leuk Lymphoma* 44 : 879-882, 2003
- 257 Yazawa Y, Takagi T, Asakura S, Suzuki K, Kano Y : Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. *J Orthop Sci* 4 : 231-237, 1999
- 258 Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y : Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. *Leukemia* 16 : 1808-1817, 2002